Akebia Therapeutics (AKBA) Capital Expenditures (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Capital Expenditures of $749000.0 for Q1 2026, up 4061.11% year-over-year from $18000.0 in Q1 2025, and down 68.8% quarter-over-quarter from $2.4 million in Q4 2025.
Akebia Therapeutics (AKBA) Capital Expenditures (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Capital Expenditures for 14 consecutive years, with $749000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 4061.11% year-over-year to $749000.0; the TTM figure through Mar 2026 stood at $3.4 million (up 375.51% YoY), while the FY2025 annual figure was $2.6 million, up 521.54% from the prior year.
- Capital Expenditures slipped to $749000.0 in Q1 2026 per AKBA's latest filing, from $2.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $10.1 million in Q3 2022 and bottomed at -$8.2 million in Q4 2023.
- Historically, Capital Expenditures has averaged $178937.5 across 5 years, with a median of $101500.0 in 2025.
- Annual changes were most pronounced in 2022 — Capital Expenditures plunged 191.4% — and 2026, when it soared 4061.11%.
- Akebia Therapeutics' Capital Expenditures stood at $10.1 million in 2022, then sank by 180.73% to -$8.2 million in 2023, then soared by 92.01% to -$653000.0 in 2024, then surged by 467.69% to $2.4 million in 2025, then sank by 68.8% to $749000.0 in 2026.
- Business Quant data shows AKBA's Capital Expenditures at $749000.0 in Q1 2026, $2.4 million in Q4 2025, and $77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.60 Mn | 92.06 Mn | 38.70 Mn | 392,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 392,000.00 |
| Jun 30, 2026 | 392,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Dec 31, 2025 | 2.40 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 77,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | -653,000.00 |
| Dec 31, 2024 | -653,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | 613,000.00 |
| Mar 31, 2024 | 613,000.00 |